Global Androgenic Alopecia Therapeutics Pipeline Analysis Report - Tucson News Now

Global Androgenic Alopecia Therapeutics Pipeline Analysis Report 2017 - Positive Clinical Results Driving Pipeline Growth

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact

SOURCE Research and Markets

DUBLIN, March 7, 2018 /PRNewswire/ --

The "Androgenic Alopecia Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other" report has been added to's offering.

Research and Markets Logo

The study analyzed that the androgenic alopecia therapeutics pipeline comprises approximately 24 active drug candidates in different stages of development.

According to the research findings, various new technology platforms are being used by the companies for developing drug candidates to treat the disease. For instance, KINect technology platform, a kinase-focused drug discovery technology platform is used to manufacture, soft Janus kinase inhibitors, a Pre-Clinical drug candidate by Aclaris Therapeutics, Inc.

The positive clinical results of androgenic alopecia drug candidates have been driving the pipeline growth. Many drug candidates have shown positive clinical results and are proceeding further towards development. In February 2016, Cassiopea S.p.A. reported the top-line results from the proof of concept, Phase II clinical trial of Breezula (CB-03-01), in androgenic alopecia and it was found that Breezula, met both its two pre-defined co-primary efficacy endpoints, increase in total area hair count within 1 cm2 (TAHC) and subject hair growth assessment (HGA) at six months. Breezula also demonstrated favorable safety profile.

In August 2017, Aclaris Therapeutics, Inc. acquired Confluence Life Sciences, Inc., a privately held biotechnology company for a consideration of $10 million in cash and issued approximately 350,000 shares of its common stock, with a value of approximately $10 million on the closing date to expand the dermatological pipeline of Aclaris Therapeutics, Inc.

Some of the key players developing drugs for the treatment of androgenic alopecia therapeutics include GlaxoSmithKline plc, Almirall S.A., Allergan plc, RepliCel Life Sciences Inc. and others.

Report Segmentation

  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company

Key Topics Covered

Chapter 1. Research Background
1.1. Research Objectives
1.2. Definition
1.3. Research Scope
1.4. Key Stakeholders

Chapter 2. Research Methodology
2.1. Secondary Research
2.2. Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1. Androgenic Alopecia Overview
4.2. Key Drivers
4.3. Key Barriers
4.4. Androgenic Alopecia Therapeutics Pipeline Analysis

Chapter 5. Androgenic Alopecia Therapeutics Pipeline Analysis by Phase (2017)
5.1. Phase III: Drug Profiles
5.2. Phase II: Drug Profiles
5.3. Phase I: Drug Profiles
5.4. Pre-Clinical: Drug Profiles
5.5. Discovery: Drug Profiles
5.6. Discontinued: Drug Profiles

Chapter 6. Clinical Trials Analysis
6.1. Clinical Trials Analysis by Region
6.2. Clinical Trials Analysis by Trial Status

Chapter 7. Competitive Landscape Analysis
7.1. Key Players Benchmarking for Androgenic Alopecia Therapeutics Pipeline
7.2. SWOT Analysis of Androgenic Alopecia Therapeutics Pipeline

Chapter 8. Company Profiles
8.1. Merck & Co. Inc.
8.2. Allergan Plc
8.3. Almirall S.A.
8.4. RepliCel Life Sciences Inc.
8.5. RiverTown Therapeutics Inc.

For more information about this report visit

Media Contact:

Research and Markets
Laura Wood, Senior Manager  

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


Cision View original content:

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly